The administration of exogenous RANKL alone did not induce a change in the expression of catabolic factors, including proinflammatory cytokines (e.g., IL-1β) and matrix-degrading enzymes (e.g., MMP-3 and -13) by human AF and NP cells. This evidence concerns the gene TNFSF11 and atrial fibrillation.